Zidovudine (drug) — Competitive Intelligence Brief

Zidovudine (drug) (Zidovudine (drug)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Infectious Disease / Virology.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

Zidovudine (drug) (Zidovudine (drug)) — Johann Wolfgang Goethe University Hospital. Zidovudine is a nucleoside reverse transcriptase inhibitor that blocks HIV replication by inhibiting the enzyme reverse transcriptase, preventing the virus from converting its RNA genome into DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Zidovudine (drug) TARGET	Zidovudine (drug)	Johann Wolfgang Goethe University Hospital	marketed	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Lamiduvine (Epivir)	Lamiduvine (Epivir)	Catholic University of the Sacred Heart	marketed	Nucleoside Reverse Transcriptase Inhibitor (NRTI)	HIV reverse transcriptase
elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil	elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil	Fundacion Clinic per a la Recerca Biomédica	marketed	Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, CYP3A4, HIV reverse transcriptase
Dolutegravir/Lamivudine as a single pill	Dolutegravir/Lamivudine as a single pill	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
emtricitabine [FTC]/tenofovir [TDF]	emtricitabine [FTC]/tenofovir [TDF]	Tibotec, Inc	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Emtricitabine/tenofovir or abacavir/lamivudine	Emtricitabine/tenofovir or abacavir/lamivudine	Fundacion SEIMC-GESIDA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Abacavir/lamivudine/zidovudine	Abacavir/lamivudine/zidovudine	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
3. ViiV Healthcare · 2 drugs in this class
4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
5. Asan Medical Center · 1 drug in this class
6. Dong-A ST Co., Ltd. · 1 drug in this class
7. Bristol-Myers Squibb · 1 drug in this class
8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
9. Fu-Sheng Wang · 1 drug in this class
10. Avexa · 1 drug in this class